BME100 s2015:Group1 9amL1

BME 100 Spring 2015	Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help
OUR TEAM Name: Shawn Striker Name: Jonathan Moreno [[ <script>(function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src = "//connect.facebook.net/en_US/all.js#xfbml=1"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));</script> <a href="https://www.facebook.com/photo.php?fbid=10201896074678317&set=a.1344680151871.44944.1677294654&type=1">Post</a> by <a href="https://www.facebook.com/grace.kim.9231">Grace Kim</a>. thumb|Name: Grace Kim]] Name: Your name Name: Your name Name: Your name LAB 1 WRITE-UP Independent and Dependent Variables Independent variable: Lipopolysaccharide Dependent variable: Protein Inflammotin Experimental Design Groups Control Group: The control group will receive a placebo on a regular basis coinciding with the prescribed drug regimen. Experimental Groups: Group 1 (Control): 0 mg Group 2: 2.5mg Group 3: 5mg Group 4: 7.5mg Group 5: 10mg Age 70-80 Number of subjects per group 100 subjects total per group; 50 male and 50 female Subject Selection Healthy (no history of alcohol or drug use, no sickness/chronic diseases, healthy weight) 70-80 years, absence of drug history that affects inflammotin. Sources of Error and Bias Other drugs being used, subjects' genetic predisposition, amount of inflammotin in the body prior to tests. Consideration of the effect of the drug due to the initial amount of inflammotin.